Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Adjuvant Capital is a venture capital firm founded to finance life science technologies aimed at addressing high-burden public health challenges. Established in New York City and Zurich, the firm focuses on improving global health through investments in innovative technologies. Their mission is to ensure that these technologies are accessible to those who need them most, particularly in low- and middle-income countries.
The firm manages an oversubscribed fund with an AUM of $300 million, confirmed as of September 30, 2023. Adjuvant Capital has a portfolio of 19 companies, emphasizing investments in sectors such as biotech, healthcare, and fintech. The firm operates from two primary locations: New York City and Zurich, allowing it to maintain a global perspective on health challenges.
Notable milestones include being listed on the ImpactAssets IA50 and receiving independent verification from BlueMark for their impact management practices. Adjuvant Capital aligns its investment strategy with the UN Sustainable Development Goals, particularly focusing on health and well-being.
Adjuvant Capital specializes in life science technologies that target neglected and high-burden infectious diseases, maternal and child health, nutrition, and reproductive and sexual health. The firm emphasizes investments in opportunities with demonstrated safety and efficacy in humans, particularly those that have reached Phase II or later clinical trials. This focus allows them to deliver significant health outcomes in underserved markets.
The firm typically invests between $10 million and $25 million per deal, targeting companies at the Seed, Series A, and Series B stages. Their geographic focus spans North America and Europe, with a particular emphasis on low- and middle-income countries. Adjuvant Capital seeks compelling proof-of-concept data before investment, ensuring that their portfolio companies can demonstrate efficacy and safety in addressing critical health challenges.
Adjuvant Capital's portfolio includes 19 companies that are addressing various health challenges. Notable portfolio companies include:
These companies reflect Adjuvant Capital's commitment to addressing high-burden public health challenges through innovative life science technologies.
Glenn Rockman: Co-Founder and Managing Partner; previously at the Global Health Investment Fund, he brings extensive experience in financing health technologies.
Kabeer Aziz: Co-Founder and Partner; has a strong background in venture capital and public health investments.
Philippe Dro: Partner; specializes in life sciences and has a track record of successful investments in the sector.
Abrar Haque: Associate; focuses on sourcing and evaluating investment opportunities in life sciences.
Giulia Balconi: Associate; involved in portfolio management and operational support for portfolio companies.
Kate Antrobus: Venture Partner; brings expertise in public health and strategic investments.
Neha Agarwal: Senior Advisor; provides insights on global health trends and investment strategies.
Markus Gemuend: Senior Advisor; has extensive experience in health technology investments.
Evelyn Yanatos: Director of Finance and Compliance; oversees financial operations and compliance.
Alexandra (Sandra) Glucksmann: Advisory Partner; offers strategic guidance and industry insights.
To pitch to Adjuvant Capital, founders should visit their contact page at adjuvantcapital.com/contact. The firm prefers to receive pitches via email at yanatos@adjuvantcapital.com. Founders should include detailed information about their technology, proof-of-concept data, and how their solution addresses public health challenges.
Response times may vary, but founders can expect to hear back within a few weeks. A warm introduction is not required but can be beneficial in establishing credibility.
In 2023, Adjuvant Capital made significant investments in several innovative companies, including:
Adjuvant Capital continues to engage actively in the life sciences sector, with a clear focus on public health technologies. Their commitment to addressing high-burden health challenges is reflected in their ongoing investment activity and portfolio growth.
What are Adjuvant Capital's investment criteria?
Adjuvant Capital invests in life science technologies that target high-burden public health challenges, particularly in low- and middle-income countries. They require compelling proof-of-concept data, typically Phase II or later clinical trial data, before making an investment.
How can founders apply or pitch to Adjuvant Capital?
Founders can submit their investment ideas through the contact page on Adjuvant Capital's website. The firm prefers to receive pitches via email at yanatos@adjuvantcapital.com.
What makes Adjuvant Capital different from other venture capital firms?
Adjuvant Capital focuses exclusively on life science technologies that address public health challenges, particularly in underserved markets. Their dual mandate emphasizes both financial returns and measurable social impact, aligning with the UN Sustainable Development Goals.
What is the geographic scope of Adjuvant Capital's investments?
The firm primarily invests in North America and Europe, with a strong emphasis on low- and middle-income countries where public health challenges are most acute.
What is the typical check size for investments?
Adjuvant Capital typically invests between $10 million and $25 million per deal, focusing on companies at the Seed, Series A, and Series B stages.
What kind of post-investment involvement does Adjuvant Capital have?
Adjuvant Capital provides not only capital but also strategic guidance and access to a network of experts in global health, ensuring that their investments lead to meaningful health outcomes.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.